Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
Browsing: Ovarian
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer.…
Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer.…
Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients…
Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients…
Earn CME: https://www.naccme.com/program/19-cpc-101-6 This webcast features a presentation by Dr. Alexander B. Olawaiye that discusses the integration of PARP inhibitors…
Heidi Gray, MD @heidigraydrezn5 of @SeattleCCA @UWashOBGYN discusses the phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy…
Curtis McCloskey, PhD of @ottawahospital explains how this affects treatment and clinicians today. __________ A laboratory study published in Clinical…
Curtis McCloskey, PhD of @ottawahospital provides insight on a possible new frontier for preventing ovarian cancer. ____________ A laboratory study published…
A laboratory study published in Clinical Cancer Research provides a new perspective on how ovarian cancer is developed and suggests…
Nearly 14,000 women will die from ovarian cancer in 2019. Now, new research has found that women who use IUDs…
Earn CME credit: https://www.naccme.com/program/2018-i7956-1 PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-03 This on-demand activity examines the implications of BRCA mutational status, BRCAness, synthetic lethality,…
Speaking about symptoms can often be a difficult experience for patients, as it can confirm their fears of the disease.…
The diagnosis of ovarian cancer often occurs in the late stages due to a lack of adequate screening facilities. However,…
Physicians who are dealing with gynecological tumors have a limited experience of how to deal with the complications and toxicity…